GSK (NYSE: GSK) reports May share repurchases, 6.49% held in treasury

Rhea-AI Filing Summary

GSK plc reports recent purchases of its own ordinary shares under its existing buyback programme, executed through Citigroup Global Markets Limited. Between 11 and 15 May 2026, the company repurchased daily amounts ranging from 323,368 to 342,412 shares at volume-weighted average prices around 1,855–1,882 GBp.

The purchased shares will be held as Treasury shares. Since 11 May 2026, GSK has bought a total of 1,671,851 ordinary shares. After these transactions, it holds 263,050,137 shares in treasury and has 4,053,167,539 ordinary shares in issue, which is also the total number of voting rights.

The company states that, in line with DTR 5.5.1R, 6.49% of voting rights are attributable to treasury shares. Shareholders can use the updated voting rights figure to assess whether they must notify their holdings under the UK Disclosure Guidance and Transparency Rules.

Key Figures

11 May 2026 repurchases: 323,368 shares at 1,855.48 GBp VWAP 12 May 2026 repurchases: 342,412 shares at 1,868.04 GBp VWAP 13 May 2026 repurchases: 333,903 shares at 1,882.24 GBp VWAP +6 more

9 metrics

11 May 2026 repurchases 323,368 shares at 1,855.48 GBp VWAP Ordinary shares bought on 11 May 2026

12 May 2026 repurchases 342,412 shares at 1,868.04 GBp VWAP Ordinary shares bought on 12 May 2026

13 May 2026 repurchases 333,903 shares at 1,882.24 GBp VWAP Ordinary shares bought on 13 May 2026

14 May 2026 repurchases 334,877 shares at 1,879.23 GBp VWAP Ordinary shares bought on 14 May 2026

15 May 2026 repurchases 337,291 shares at 1,874.08 GBp VWAP Ordinary shares bought on 15 May 2026

Shares bought since 11 May 2026 1,671,851 shares Aggregate repurchases under buyback programme

Treasury shares after purchases 263,050,137 shares Ordinary shares held in treasury after buybacks

Voting rights outstanding 4,053,167,539 voting rights Ordinary shares in issue excluding treasury

Treasury voting rights percentage 6.49% Voting rights attributable to treasury shares

Key Terms

Treasury shares, Market Abuse Regulation, Disclosure Guidance and Transparency Rules, DTR 5.5.1R, +1 more

5 terms

Treasury shares financial

"The purchased shares will be held as Treasury shares."

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

Market Abuse Regulation regulatory

"In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014..."

Market abuse regulation consists of laws and rules designed to prevent dishonest or manipulative practices in financial markets. It aims to ensure fair and transparent trading, so investors can trust that markets operate honestly, much like rules that keep a game fair. By reducing unfair advantages, it helps protect investor confidence and promotes healthy, efficient markets.

Disclosure Guidance and Transparency Rules regulatory

"under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules."

Disclosure guidance and transparency rules are the standards and regulations that require companies to share clear, timely information about their finances, risks, operations and material events. They matter to investors because consistent, honest reporting is like a car’s dashboard — it reveals the data you need to judge safety and performance and make informed buying or selling decisions. Strong disclosure reduces surprises and helps keep markets fair and efficient.

DTR 5.5.1R regulatory

"The Company confirms that, in accordance with DTR 5.5.1R, following the above purchases..."

voting rights financial

"the total number of voting rights in the Company will be 4,053,167,539."

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Transaction in own shares

GSK plc (the "Company") announces today acting through Citigroup Global Markets Limited (the "Broker"), it has purchased the following number of the Company's ordinary shares of 31¼ pence each.

Date of purchase	Aggregate number of ordinary shares of 31 ¼ pence each purchased	Lowest price paid per share (GBp)	Highest price paid per share (GBp)	Volume weighted average price paid per share (GBp)
11 May 2026	323,368	1,841.00	1,869.00	1,855.48
12 May 2026	342,412	1,827.00	1,887.50	1,868.04
13 May 2026	333,903	1,865.50	1,897.00	1,882.24
14 May 2026	334,877	1,869.00	1,890.00	1,879.23
15 May 2026	337,291	1,855.50	1,899.50	1,874.08

The purchased shares will be held as Treasury shares.

Such share purchases form part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 8 May 2026, as announced on 11 May 2026.  Since 11 May 2026 the Company has purchased 1,671,851 ordinary shares.

Following the above purchases, the Company will hold 263,050,137 ordinary shares in treasury and have 4,053,167,539 ordinary shares in issue (excluding Treasury shares).

Following the above purchases, the total number of voting rights in the Company will be 4,053,167,539. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Company confirms that, in accordance with DTR 5.5.1R, following the above purchases the percentage of voting rights attributable to the ordinary shares held in treasury is 6.49 per cent.

In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended, a full breakdown of the individual purchases of ordinary shares made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) is set out in the Schedule to this announcement, available via the link below:

http://www.rns-pdf.londonstockexchange.com/rns/7738E_1-2026-5-18.pdf

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

GSK enquiries
Media:	Tim Foley	+44 (0) 20 8047 5502	(London)
	Kathleen Quinn	+1 202 603 5003	(Washington DC)
Investor Relations:	Constantin Fest	+44 (0) 7831 826525	(London)
	James Dodwell	+44 (0) 20 8047 2406	(London)
	Mick Readey	+44 (0) 7990 339653	(London)
	Steph Mountifield	+44 (0) 7796 707505	(London)
	Sam Piper	+44 (0) 7824 525779	(London)
	Jeff McLaughlin	+1 215 751 7002	(Philadelphia)
	Frannie DeFranco	+1 215 751 3126	(Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025, and GSK's Q1 Results for 2026.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: May 18, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What share repurchases did GSK (GSK) report for May 2026?

GSK reported buying its own ordinary shares between 11 and 15 May 2026. Daily repurchases ranged from 323,368 to 342,412 shares at volume-weighted average prices near 1,855–1,882 GBp, as part of its existing buyback programme.

How many GSK (GSK) shares have been repurchased since 11 May 2026?

Since 11 May 2026, GSK has repurchased 1,671,851 ordinary shares. These shares are being held as Treasury shares and form part of the company’s ongoing share buyback programme executed through Citigroup Global Markets Limited.

What is GSK’s (GSK) current number of voting rights after the buybacks?

Following the reported share purchases, GSK has 4,053,167,539 ordinary shares in issue, which equals the total number of voting rights. Shareholders can use this figure as the denominator for UK disclosure threshold calculations.

What percentage of GSK (GSK) voting rights are held in treasury shares?

GSK confirms that 6.49% of its voting rights are attributable to ordinary shares held in treasury. This percentage is calculated in accordance with DTR 5.5.1R and reflects the impact of the recent share repurchases.

Why are GSK’s (GSK) May 2026 share repurchases executed via a broker?

The buybacks are carried out by Citigroup Global Markets Limited under a non-discretionary agreement. This arrangement allows GSK’s share repurchases on exchanges like the London Stock Exchange in accordance with Market Abuse Regulation Article 5 requirements.